Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: Efficacy and toxicity

Clinical Genitourinary Cancer

Volumn 12, Issue 4, 2014, Pages 262-269

  Bellmunt, Joaquim ^a,b   Pons, Francesc ^b   Foreshew, Abigail ^c   Fay, André P ^a   Powles, Thomas ^c   Porta, Camillo ^d   Bracarda, Sergio ^e   Lampron, Megan E ^a   Cerbone, Linda ^f   Sternberg, Cora N ^f   Hutson, Thomas E ^g   Choueiri, Toni K ^g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL DEL MAR   (Spain)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e ISTITUTO TOSCANO TUMORI   (Italy)

^f Ospedale S Camilo Forlanini   (Italy)

^g TEXAS ONCOLOGY   (United States)

Author keywords

mTOR inhibitor; Pazopanib; Renal cell carcinoma; Sequential therapy; VEGF targeted therapy

Indexed keywords

BEVACIZUMAB; CEDIRANIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; NICOTINAMIDE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT FAILURE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, RENAL CELL; CLINICAL TRIAL; FOLLOW UP; KIDNEY NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SIROLIMUS; SULFONAMIDES; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904723196     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.03.002     Document Type: Article

References (31)

1. T.K. Choueiri Renal cell carcinoma Hematol Oncol Clin North Am 25 2011 xiii-xiv
2. N.K. Janzen, H.L. Kim, R.A. Figlin, and A.S. Belldegrun Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin N Am 30 2003 843 852
3. K.D. Courtney, and T.K. Choueiri Updates on novel therapies for metastatic renal cell carcinoma Ther Adv Med Oncol 2 2010 209 219
4. W.G. Kaelin Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer Clin Cancer Res 10 2004 6290S 6295S
5. S. Biswas, H. Troy, and R. Leek et al. Effects of HIF-1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts J Oncol 2010 2010 757908
6. W.G. Kaelin Jr. The von Hippel-Lindau tumor suppressor protein: an update Methods Enzymol 435 2007 371 383
7. D.Y. Heng, and T.K. Choueiri The evolving landscape of metastatic renal cell carcinoma Am Soc Clin Oncol Educ Book 2012 299 302
8. R.J. Motzer, T.E. Hutson, and D. Cella et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 2013 722 731
9. B.J. Escudier, C. Porta, and P. Bono et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) - PISCES study, NCT 01064310 J Clin Oncol 30 2012 (abstract CRA4502)
10. C. Griffiths, N. Hay, F. Sutcliffe, and A. Stevens NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma Lancet Oncol 12 2011 221 222
11. R.J. Motzer, N. Agarwal, and C. Beard et al. NCCN clinical practice guidelines in oncology: kidney cancer J Natl Compr Canc Netw 7 2009 618 630
12. G. Sonpavde, T.K. Choueiri, and B. Escudier et al. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 61 2012 307 316
13. T.K. Choueiri, A. Fay, and R. Gagnon et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma Clin Cancer Res 19 2013 5218 5226
14. A. Ravaud, M. Gross-Goupil, and J. Bellmunt Combination therapy in metastatic renal cell cancer Semin Oncol 40 2013 472 481
15. M.M. Vickers, T.K. Choueiri, and M. Rogers et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy Urology 76 2010 430 434
16. R.J. Motzer, B. Escudier, and S. Oudard et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
17. B.I. Rini, B. Escudier, and P. Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
18. Hutson TE, Escudier B, Esteban E, et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from INTORSECT trial. The 37th European Society of Medical Oncology Congress 2012 (abstract LBA22-PR).
19. C. Porta, G. Procopio, and G. Carteni et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases BJU Int 108 2011 E250 E257
20. M.P. Sablin, S. Negrier, and A. Ravaud et al. Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34
21. A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
22. C. Eichelberg, R. Heuer, and F.K. Chun et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis Eur Urol 54 2008 1373 1378
23. D.R. Shepard, B.I. Rini, and J.A. Garcia et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab J Clin Oncol 26 2008 (abstract 5123)
24. G. Di Lorenzo, G. Carteni, and R. Autorino et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 2009 4469 4474
25. T. Powles, and S.M. Crusz Sequencing systemic therapies in advanced RCC J Clin Oncol 2013 2013 172 174
26. J.B. Brugarolas, F. Vazquez, A. Reddy, W.R. Sellers, and W.G. Kaelin Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways Cancer Cell 4 2003 147 158
27. R.J. Motzer, C.H. Barrios, and T.M. Kim et al. Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC) J Clin Oncol 31 2013 (abstract 4504)
28. T.E. Hutson, and R.A. Figlin Novel therapeutics for metastatic renal cell carcinoma Cancer 115 suppl 10 2009 2361 2367
29. T.E. Hutson, R.M. Bukowski, C.L. Cowey, R. Figlin, B. Escudier, and C.N. Sternberg Sequential use of targeted agents in the treatment of renal cell carcinoma Crit Rev Oncol Hematol 77 2011 48 62
30. R.M. Bukowski, F.F. Kabbinavar, and R.A. Figlin et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 2007 4536 4541
31. D.Y. Heng, M.J. Mackenzie, and U.N. Vaishampayan et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy Ann Oncol 23 2012 1549 1555